Stocks Health care PCVX
NASDAQ · Health careVaxcyte, Inc. (PCVX)
It posted a net loss of $1.1B. In fiscal 2025 capital spending exceeded operating cash flow by $669.3M. At September 30, 2026 it held $125.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Vaxcyte, Inc.
- Net worth
- Vaxcyte, Inc. has a market value (market cap) of $10B at the latest share price, and shareholders' equity of $2.5B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $655.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Vaxcyte, Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Vaxcyte, Inc. does
Vaxcyte, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker PCVX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$766.6M | -$5.63 | -$669.3M |
| 2024 | n/a | -$463.9M | -$3.80 | -$475.1M |
| 2023 | n/a | -$402.3M | -$4.14 | -$312.9M |
| 2022 | n/a | -$223.5M | -$3.44 | -$176.4M |
| 2021 | n/a | -$100.1M | -$1.93 | -$127.9M |
| 2020 | n/a | -$89.2M | -$3.02 | -$47.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Vaxcyte, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026
- November 4, 2026
- October 9, 2026Material agreement8-KVaxcyte completed concurrent public offerings of convertible senior notes and common stock to raise capital.
- October 6, 2026Form 305B2 filing 305B2
- October 5, 2026
- September 3, 2026
- August 11, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Vaxcyte, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Exercised options | 2,250 | $12K |
| November 2, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Soldpre-planned (10b5-1) | 1,907 | $115.9K |
| November 2, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Soldpre-planned (10b5-1) | 343 | $21.1K |
| November 2, 2026 | Cowan ElviaSVP, Finance & CAO | Exercised options | 3,000 | $77.8K |
| November 2, 2026 | Cowan ElviaSVP, Finance & CAO | Soldpre-planned (10b5-1) | 2,414 | $146.7K |
| November 2, 2026 | Cowan ElviaSVP, Finance & CAO | Soldpre-planned (10b5-1) | 586 | $36.1K |
| October 5, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Exercised options | 18,000 | $96.3K |
| October 5, 2026 | Wassil JimEVP, Chief Scientific Ofc, COO | Soldpre-planned (10b5-1) | 18,000 | $1.6M |
Who owns PCVX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 14.4% | August 6, 2026 |
| JANUS HENDERSON GROUP Ltd.13G, passive | 12.1% | August 11, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 8.9% | May 15, 2026 |
| T. Rowe Price Investment Management, Inc.13G, passive | 8.6% | February 17, 2026 |
| Vanguard Capital Management13G, passive | 5.03% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 331 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 20,852,907 | +4,360,046 |
| Jupiter Topco LLC | 17,965,847 | new |
| BlackRock, Inc. | 12,068,129 | +1,096,313 |
| RA Capital Management, L.P. | 11,474,599 | 0 |
| Wellington Management Group Llp | 7,001,565 | +1,386,968 |
| Vanguard Portfolio Management LLC | 6,593,551 | +314,006 |
| Vanguard Capital Management LLC | 6,348,679 | +81,978 |
| State Street Corp | 5,351,698 | +911,179 |
| Deep Track Capital, LP | 4,300,000 | 0 |
| Geode Capital Management, LLC | 3,459,363 | +258,080 |
| Kynam Capital Management, LP | 2,922,335 | 0 |
| Westfield Capital Management Co LP | 2,472,428 | -1,173,710 |
| Caligan Partners LP | 2,188,636 | +127,917 |
| Paradigm Biocapital Advisors LP | 2,127,852 | -2,665,168 |
| Bellevue Group AG | 1,971,935 | +781,238 |
| D. E. Shaw & Co., Inc. | 1,901,872 | -963,446 |
| Maverick Capital Ltd | 1,613,242 | +235,504 |
| Charles Schwab Investment Management Inc | 1,464,812 | +60,864 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,425,470 | +53,045 |
| Eventide Asset Management, LLC | 1,380,219 | +5,927 |
Insiders
14 insiders reported holding 1,094,936 shares in total, about $73.9M at the last price.
| Holder | Shares |
|---|---|
| Pickering GrantCHIEF EXECUTIVE OFFICER, Director | 563,117133,215 held indirectly |
| Guggenhime AndrewPRESIDENT AND CFO | 157,16661,850 held indirectly |
| Wassil JimEVP, Chief Scientific Ofc, COO | 145,435 |
| Dhaliwal Harpreet S.Chief Technical Ops Officer | 68,085 |
| Jodar LuisChief Medical Officer | 52,632 |
| Cowan ElviaSVP, Finance & CAO | 27,860 |
| Lukatch HeathDirector | 19,481 |
| Drapeau Anne SDirector | 12,481 |
| Loxam TeriDirector | 12,481 |
| Gilbert Halley EDirector | 12,481 |
Questions about PCVX
What does Vaxcyte, Inc. do?
Vaxcyte, Inc. is a company in the Health care sector, listed on NASDAQ as PCVX. Its shares trade on NASDAQ under the ticker PCVX.
What is Vaxcyte, Inc.'s net worth?
Vaxcyte, Inc. has a market value (market cap) of $10B at the latest share price, and shareholders' equity of $2.5B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Vaxcyte, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $1.1B.
When did Vaxcyte, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 6, 2026.
When is Vaxcyte, Inc.'s next earnings report?
Vaxcyte, Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PCVX with
Follow PCVX
Get an email when Vaxcyte, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Vaxcyte, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.